Business
Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics
PRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and
About this update from Eirgenix, Inc.
[{"type":"text","content":"PRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and manufacturing company.","length":523,"tagName":"p"},{"type":"text","content":"Under the agreement, Transcenta will grant EirGenix a non-exclusive license to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how, and regulatory support packages. Transcenta will be eligible to receive a substantial upfront and milestone payments, as well as future royalty payments associated with the commercial use of the licensed technologies, reflecting the long-term value both companies expect to create through this collaboration.","length":631,"tagName":"p"},{"type":"text","content":"The HiCB platform is designed to deliver greater process efficiency, improve process control and product consistency, and significantly reduce cost of goods compared to conventional fed-batch manufacturing process, ultimately contributing to expanded global patient access to high-quality, affordable biologics.","length":311,"tagName":"p"},{"type":"text","content":"Under this collaboration, EirGenix will adopt Transcenta’s HiCB platform to support its biologics development programs and manufacturing operations. EirGenix plans to apply the HiCB platform to serve CDMO clients pursuing intensified and continuous manufacturing solutions.","length":273,"tagName":"p"},{"type":"text","content":"“We are pleased to share our HiCB platform, a result of Transcenta’s leadership in highly intensified continuous bioprocessing, with partners who share our vision of transforming biologics manufacturing,” said Dr. Xueming Qian, Chairman and CEO of Transcenta. “By enabling others to implement HiCB, we can collectively advance affordability of and global access to innovative biologics. The proceeds from thi...